Altcoin Expansion Planned for Hashdex's US Crypto ETF

Monday 17th of March 2025 16:31:19

Hashdex Seeks to Expand US Crypto ETF to Include Litecoin, XRP, and Other Altcoins

March 17, 2025 - Hashdex, a leading provider of cryptocurrency-based exchange-traded funds (ETFs), has announced plans to expand its flagship US Crypto ETF to include a broader range of altcoins, including Litecoin, XRP, and other popular digital assets.

The move comes as part of Hashdex's ongoing efforts to provide investors with a more diversified and comprehensive exposure to the rapidly evolving cryptocurrency market. The expanded ETF, which is expected to launch in the coming months, will track a market-capitalization-weighted index of major altcoins, in addition to Bitcoin and Ethereum.

"We're excited to bring more diversity and liquidity to the cryptocurrency space," said Hashdex CEO, Josh Gancher. "By including Litecoin, XRP, and other altcoins, we're providing investors with a more comprehensive view of the market and the opportunity to diversify their portfolios."

The expanded ETF will track the Hashdex Altcoin Index, which will include a range of altcoins with market capitalizations above $1 billion. The index will be rebalanced quarterly to ensure that the ETF remains aligned with the market's shifting dynamics.

The inclusion of Litecoin, XRP, and other altcoins in the ETF is expected to attract a broader range of investors, including those who may have previously been hesitant to invest in cryptocurrency due to concerns about volatility or lack of diversification.

Hashdex's US Crypto ETF has been one of the most successful cryptocurrency-based ETFs in the market, with over $1 billion in assets under management. The company's expansion into altcoins is seen as a major step forward in its mission to provide investors with a comprehensive and diversified exposure to the cryptocurrency market.

The expanded ETF is expected to be listed on major US exchanges, including the New York Stock Exchange (NYSE) and the NASDAQ, pending regulatory approval.